Saphnelo®

Understanding Saphnelo® 

Saphnelo® (anifrolumab-fnia) is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE)in adults who are receiving standard therapy. As an interferon (IFN) receptor antagonist, Saphnelo® blocks type I interferon signaling, a key driver of inflammation and immune dysfunction in lupus.

How Saphnelo® Works:

• Blocks type I interferon signaling, reducing inflammation and autoimmune activity
• Helps manage lupus symptoms in patients receiving standard therapy
• Targets a key driver of immune dysfunction in SLE, providing a more precise treatment approach

FDA Approval:

• Saphnelo® (anifrolumab-fnia): Approved in August 2021 for the treatment of SLE in adults receiving standard therapy.

For more information, please visit the Saphnelo® patient website and speak with your healthcare provider to determine if Saphnelo® is the right treatment option for you.